Leerink Partnrs Has Positive Forecast for HIMS Q4 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Leerink Partnrs upped their Q4 2024 earnings estimates for shares of Hims & Hers Health in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.11 per share for the quarter, up from their previous forecast of $0.07. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.16 EPS, FY2026 earnings at $0.67 EPS and FY2027 earnings at $0.99 EPS.

HIMS has been the topic of a number of other research reports. Piper Sandler restated a “neutral” rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Truist Financial upped their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday. Finally, TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $23.62 on Wednesday. The business’s 50-day moving average is $18.40 and its 200 day moving average is $18.29. Hims & Hers Health has a 1 year low of $6.58 and a 1 year high of $25.74. The firm has a market capitalization of $5.07 billion, a P/E ratio of 54.80 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the firm posted ($0.04) earnings per share. The business’s quarterly revenue was up 77.1% on a year-over-year basis.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC boosted its position in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC lifted its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Arizona State Retirement System grew its stake in Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after acquiring an additional 1,173 shares during the period. Victory Capital Management Inc. increased its holdings in Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after acquiring an additional 1,212 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the sale, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 854,547 shares of company stock valued at $15,987,230 in the last quarter. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.